Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 1/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 9/20 | 0.49 |
| ▸ | GAA | P10253 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1964835 | 0.83 | ALOX5 (0.46) | ADORA1ALOX5GAAALDH1A1MAPT | |
| SCHEMBL13464371 | 0.83 | ALOX5 (0.46) | ADORA1ALOX5GAAALDH1A1PABPC1 | |
| SCHEMBL6943398 | 0.76 | BACE1 (0.47) | ADORA1ALOX5GAAALDH1A1PABPC1 | |
| SCHEMBL5166144 | 0.76 | ADORA1 (0.57) | ADORA1ALOX5GAAALDH1A1PABPC1 | |
| SCHEMBL7975156 | 0.75 | ADORA1 (0.81) | ADORA1ALOX5GAAALDH1A1MAPT | |
| SCHEMBL2986663 | 0.74 | ADORA1 (0.79) | ADORA1ALOX5GAAALDH1A1MAPT | |
| SCHEMBL5168342 | 0.71 | ALOX5 (0.82) | ADORA1ALOX5GAAALDH1A1MAPT | |
| SCHEMBL2987486 | 0.70 | ALOX5 (0.62) | ADORA1ALOX5GAAMAPTTRIM33 | |
| SCHEMBL2983468 | 0.70 | ALOX5 (0.62) | ADORA1ALOX5GAAALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL5167314 | 0.70 | ALOX5 (0.80) | ADORA1ALOX5GAAALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6849642-B2 | Bicyclic imidazo-3-yl-amine derivatives substituted on the 6-membered ring | GRUENENTHAL GMBH (DE) | 2005-02-01 | — | — | US | claimed |
| EP-1218380-B1 | BICYCLIC IMIDAZO-3-YL-AMINE DERIVATIVES WHICH ARE SUBSTITUTED ON THE SIXTH RING | GRUENENTHAL GMBH (DE) | 2003-12-17 | — | — | EP | claimed |
| JP-2003517466-A | — | — | 2003-05-27 | — | — | JP | claimed |
| US-20020183327-A1 | Bicyclic imidazo-3-yl-amine derivatives substituted on the 6-membered ring | GRUENENTHAL GMBH. | 2002-12-05 | — | — | US | claimed |
| EP-1218380-A2 | BICYCLIC IMIDAZO-3-YL-AMINE DERIVATIVES WHICH ARE SUBSTITUTED ON THE SIXTH RING | Grünenthal GmbH (DE) | 2002-07-03 | — | — | EP | claimed |
| WO-2001027110-A2 | BICYCLIC IMIDAZO-3-YL-AMINE DERIVATIVES WHICH ARE SUBSTITUTED ON THE SIXTH RING | Grünenthal GmbH (DE) | 2001-04-19 | — | — | WO | claimed |
| US-6849642-B2 | Bicyclic imidazo-3-yl-amine derivatives substituted on the 6-membered ring | GRUENENTHAL GMBH (DE) | 2005-02-01 | — | — | US | disclosed |
| EP-1218380-B1 | BICYCLIC IMIDAZO-3-YL-AMINE DERIVATIVES WHICH ARE SUBSTITUTED ON THE SIXTH RING | GRUENENTHAL GMBH (DE) | 2003-12-17 | — | — | EP | disclosed |
| US-20020183327-A1 | Bicyclic imidazo-3-yl-amine derivatives substituted on the 6-membered ring | GRUENENTHAL GMBH. | 2002-12-05 | — | — | US | disclosed |
| EP-1218380-A2 | BICYCLIC IMIDAZO-3-YL-AMINE DERIVATIVES WHICH ARE SUBSTITUTED ON THE SIXTH RING | Grünenthal GmbH (DE) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001027110-A2 | BICYCLIC IMIDAZO-3-YL-AMINE DERIVATIVES WHICH ARE SUBSTITUTED ON THE SIXTH RING | Grünenthal GmbH (DE) | 2001-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183327-A1 | Bicyclic imidazo-3-yl-amine derivatives substituted on the 6-membered ring | OPRK1, GRIN3A, OPRM1 | ADORA1 556/4885ALOX5 2675/4885GAA 3464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.